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Background: Most women in developing countries have never attended cervical screening programmes and often
little information exists on type-specific human papillomavirus (HPV) prevalence among these populations. Self-
sampling for HPV testing (self-HPV) using a dry swab may be useful for establishing a screening program and
evaluating HPV prevalence. Our aim was to evaluate self-HPV using a dry swab stored at room temperature.
Methods: This community-based study in Madagascar consisted of 449 women aged 30–65. Eligible women were
provided a dry swab to perform self-HPV. HPV analysis was accomplished by two different real-time PCR tests using
the same extracted DNA from the samples.
Results: Overall, 52 (11.6 %) specimens were invalid for HPV detection. The delay between sampling and laboratory
processing of DNA extraction considerably increased invalid results. Overall HPV prevalence of 14 hrHPV types
detected by the two PCR tests was found to be 38.2 % (n = 152). Distribution of 19 hrHPV and 9 low-risk HPV
(lrHPV) types revealed most frequently 53 and 68 among hrHPV and HPV 54, HPV 70 and HPV 42 among lrHPV.
Agreement between the two PCR methods for any of the 14 high-risk HPV (hrHPV) strains detected was 89.9 %
(kappa = 0.77, 95 % CI: 0.71–0.84). In 385 (85.7 %) samples the DNA load of ß-globin demonstrated a signal with
medium or high level copies. Conversely, in 28 (60.9 %) invalid samples the signal was undetectable. The HPV-DNA
load signal was predominantly of intermediate level (58.5 %, n = 218).
Conclusions: Self-HPV using a dry swab stored at room temperature could be a useful method for HPV screening
and for conducting population-based surveys on HPV prevalence in resource-poor settings.
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The high sensitivity of clinically validated HPV tests to-
gether with the limitations associated with a Pap test [1],
led to the recommendation of HPV testing as a replace-
ment of cytology for primary screening in the past
decade [2]. Besides these issues, logistic difficulties to
introduce cytology-based screening programs in low-
and medium-income countries (LMIC) led to the valid-
ation of high-risk HPV (hrHPV) testing as an alternative* Correspondence: rosapintocatarino@gmail.com
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[3]. However, a screening program is only successful when
most of the eligible women participate. In LMIC, many
women are unable to visit healthcare facilities, and cer-
vical cancer (CC) screening programs requiring speculum
examination are difficult to implement because of logis-
tical issues. A promising alternative for these women is
screening by means of self-HPV testing (self-HPV) [4].
Several studies have shown that Self-HPV is acceptable
to women [5–7] and compares favourably to clinician-
collected specimens [5, 8–10]. A recent meta-analysis
showed that when PCR-based HPV tests were used, the
clinical performance of self-HPV was similar toicle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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device used [11].
Self-HPV implementation in LMIC requires a careful
analysis of logistics. The choice of HPV test and collec-
tion device is of paramount importance. Optimization of
transport and storage still remains a challenging issue.
Most of the collection devices are stored in specimen
transport medium or liquid-based cytology media, which
preserve HPV-DNA at room temperature but are expen-
sive and unavailable in a resource-poor context. Add-
itionally, they are toxic and flammable and spillage and
leakage can happen during collection and transit.
Compared with liquid media, dry swabs have the ad-
vantage of being less expensive and not requiring a spe-
cial media, so the sample can be safely transported at
ambient temperature. Studies demonstrated a good
agreement (70–92 %) for HPV detection between dry
and wet swabs [12–15].
The goal of this study was to determine, within field
conditions of CC screening in Madagascar, the validity
of HPV detection in self-obtained samples using a dry
swab stored at room temperature. Additionally, we ana-
lysed HPV prevalence and genotype distribution among
the screened population.Methods
Study setting
The study was conducted by the University of Geneva in
collaboration with Madagascar’s Health and Family Plan-
ning Ministry and the Saint-Damien Healthcare Centre in
Ambanja, a mainly rural area with 125,056 inhabitants.
All participants signed an informed consent form be-
fore inclusion. The study was conducted from February
to March 2015 in the Saint-Damien Healthcare Centre.
Ethical approval of the study was obtained from the
Malgasch National Commission for the Ethics of Science
and Technology, as well as from the Ethical Cantonal
Board of Geneva, Switzerland (CER: 14–071).Study participants and procedures
We recruited 449 women aged between 30 and 65 years.
Exclusion criteria were former conisation or hysterec-
tomy and pregnancy beyond 20 weeks.
Participants received educational intervention on can-
cer and HPV infection. It was followed by information
on how to use the self-HPV, written in the local dialect
language. At the same time the participants received a
sterile, cotton-tipped swab in a dry, labelled tube. Self-
HPV was always performed without supervision. Then
participants were invited to answer a questionnaire re-
garding socio-demographic information. HPV tests were
analysed in Switzerland. HPV test analysis was done in a
minimum time of 15 days after the sampling.HPV-negative women were informed that they were
not at risk for CC and that they would not require a test
within the next 5 years. HrHPV-positive women were in-
vited for colposcopic examination. A biopsy on aceto-
white lesions coupled with endocervical curettage was
performed, or a biopsy at the 6 o’clock position and
endocervical curettage if colposcopy was normal. Treat-
ment and follow-up was proposed according to the
histological diagnosis. In case of an invalid result,
women were asked to repeat their self-sampling. Hist-
ology was also analysed in Switzerland.
Laboratory methods
Upon arrival to the laboratory, the swabs were sus-
pended in 4.3 mL of cobas® PCR media and were pulse
vortexed for 3 × 10 s. A volume of 400 μL of each sample
was used for DNA extraction and the rest of the sample
was stored at 4 °C. DNA extraction was carried out
using the cobas® HPV Test (Roche Molecular Systems).
Nucleic extracts were then stored at −20 °C.
HPV analysis was accomplished by two different real-
time PCR tests: the cobas® HPV Test (cobas) and the
Anyplex™ II HPV28 (H28) test (Seegene, Seoul, South
Korea), using the same extracted DNA from samples.
Amplification and detection were first carried out with
cobas (at Biopath Lab, Lausanne), which detects 12
pooled hrHPV genotypes (HPV 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, and 68) and concurrently provides separate
results for HPV-16 and HPV-18. The detection is based
on amplification of the L1 gene and TaqMan probes [16].
The human reference gene ß-globin s also detected.
Amplification and detection using the stored DNA ex-
tracts were then performed with the H28 test using the
CFX96™ real-time thermocycler (at Buhlmann Labora-
tories AG Schönenbuch, Switzerland). Data recording
and interpretation were automated. Details of the pro-
cedure and evaluation were described by Estrade et al.
[17], Kim et al. [18] and Kwon et al. [19].
H28 is a semi-quantitative real-time multiplex PCR
assay for screening and HPV genotyping. This test uses
Dual Priming Oligonucleotides (DPO™) and Tagging
Oligonucleotide Cleavage and Extension (TOCE™) tech-
nologies and allows to simultaneously detect 19 high-risk
HPVs (including types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52,
53, 56, 58, 59, 66, 68, 69, 73 and 82) and 9 low-risk HPVs
(including types 6, 11, 40, 42, 43, 44, 54, 61 and 70). ß-glo-
bin is also detected for internal control of assay validity.
Knowledge of the step at which the melting curve be-
comes positive allows for semi-quantification of the
DNA load of ß-globin gene and HPV genomes, from low
(+; positive after 40 PCR cycles, <102 copies/reaction), to
intermediate (++; positive within 31 to 39 PCR cycles, ≥102
and < 105 copies/reaction), to high (+++; positive before 31
PCR cycles, ≥ 105 copies/reaction) (17).
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Data were analysed with STATA 13 software package
(StataCorp, Texas, USA).
Inter-rater agreement statistics and kappa coefficient
with 95 % confidence intervals, percent total agreement
and percent positive agreement were calculated for the
paired results obtained by the cobas and H28 tests. The
calculation was restricted to 14 hrHPV.
The trend of association between HPV results and DNA
load was evaluated with the chi-square test. We also eval-
uated the effect of transport time on sample degradation
by applying a Kaplan–Meier failure estimate.
The HPV prevalence was calculated from the number
of positive cases divided from the number of tested spec-
imens by both PCR methods. HPV positivity was distrib-
uted by age-group.
HPV type distribution in single and multiple infec-
tions of 19 hrHPVs and 9 lrHPVs was explored using
the H28 test.Results
Sample characteristics
The study included 449 self-obtained swab specimens
from women whose median age was 43 (IQR: 36–51).
Overall, 52 (11.6 %) specimens were invalid for HPV de-
tection, 44 (9.8 %) were invalid for cobas, 46 (10.0 %)
were invalid for H28 and 38 (73.1 %) were concordantly
classified as invalid: 6 were invalid by H28 but negative
by cobas, 5 were invalid by cobas but negative by H28, 1
was invalid by cobas but positive by H28 and 2 were in-
valid by H28 but positive by cobas (data not shown).
The overall prevalence for the 14 hrHPV types de-
tected by one of the two methods was 38.2 % (152/397);
19.7 % (30/152) of samples were positive for HPV-16/18,
while 88.2 % (134/152) were positive for the pooled 12
hrHPV types. The overall prevalence for 19 hrHPV and
9 lrHPV was 51.8 % (209/403); the prevalence for
hrHPV only was 38.6 % (156/403).
Overall, 96 HPV-positive patients came to the colpos-
copy clinic. There were 6 (6.3 %) cervical intraepithelial
neoplasia grade 1 (CIN1), 4 (4.2 %) CIN grade 2 (CIN2), 4
(4.2 %) CIN grade 3 (CIN3) and 2 (2.1 %) squamous cell
carcinomas. The overall CIN2 or more severe (CIN2+)
prevalence was 10.4 %.Agreement between cobas and H28 for HPV-DNA detection
by type categories
The agreement was 89.9 % for any HPV type, 97.5 % for
HPV-16/18 and 90.7 % for the category with HPV
pooled types. The proportion of positive agreement was
84.8, 80.0 and 84.0 % for any hrHPV, HPV-16/18 and
pooled HPVs, respectively (Table 1).H28 test results and semi-quantification of ß-globin and
HPV-DNA load, stratified on delay between sampling and
laboratory processing of DNA extraction (2 to ≥4 weeks)
Overall, in 85.7 % of the samples the DNA load of ß-glo-
bin demonstrated a signal with medium- or high-level
copies. In 60.9 % of invalid samples the signal was un-
detectable. For 7 HPV-positive cases the ß-globin was un-
detectable (Table 2). There were no significant differences
in the number of invalid samples nor in DNA load of ß-
globin between pre- (≤50 years) and postmenopausal
(>50 years) women (p = 0.834 and p = 0.290, respectively).
The delay between sampling and laboratory processing
increased invalid results from 5.7 % after 2 weeks to 9.4 %
after 3 weeks and 12.6 % after ≥4 weeks (p = 0.177). The
mean delay between sampling and laboratory processing
was 22.7 ± 0.35 days for valid samples and 24.3 days for in-
valid samples (p = 0.129). In Fig. 1, a Kaplan–Meier failure
estimate showing a clear increase in the proportion of in-
valid tests with time.
Analysis of the relationship between HPV positive test
results and DNA load (Table 3) showed that the strength
of the load signal was predominantly intermediate
(58.5 %). The delay between sampling and DNA extraction
did not interfere on the strength of the signal (p = 0.206).
The strength of the HPV-DNA load was not related to the
strength of the ß-globin DNA load (p = 0.154). There were
no significant differences in HPV-DNA load between pre-
and postmenopausal women (p = 0.806) (data not shown).
Age-specific HPV prevalence according to cobas and H28
real-time PCR tests
The overall prevalence for 14 hrHPV types was found to
be 32.1 % with cobas and 29.5 % with H28. Stratification
by age demonstrates a decrease from the age group of 30–
35 years to the age group 36–45 years. Then a rebound is
observed in the age group of 46–55 years, followed by a
decrease in the age group of 56–65 years (Fig. 2).
Type-specific prevalence in mono- and multi-infections
according to H28 real-time PCR test (Table 4)
Overall, 31.6 % of the HPV infections were single whereas
68.4 % were multiple. Sixty-one percent of women’s infec-
tions revealed hrHPV, particularly HPV-53 and 68, followed
by HPV-73, HPV-52, HPV-35, HPV-16, HPV-33, HPV-31
and HPV-18 in decreasing order. Infections with low risk
types disclosed particularly HPV-54, HPV-70 and HPV-42,
followed by HPV-44, HPV-40 and HPV-6 in decreasing
order. There were no significant differences in the distribu-
tion of mono-infections vs. multi-infections for hr- and
lrHPVs (p = 0.300 and p = 0.202, respectively).
Discussion
In Madagascar, besides the lack of effective CC screen-
ing, population-based surveys on HPV prevalence are
Table 1 Agreement between cobas and H28 for HPV-DNA detection by type categories
Results cobas/H28 HPV distribution by type categories
N (%) Any hrHPVa HPV16/18b Pool: 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 66, 68
Pos/Pos 112 20 97
Pos/Neg 16 5 15
Neg/Pos 24 5 22
Neg/Neg 245 367 263
Total 397 397 397
Kappa (95 % CI) 0.77 (0.71–0.84) 0.79 (0.66–0.92) 0.77 (0.71–0.84)
% Total Agreement 89.9 97.5 90.7
% Positive Agreementc 84.8 80.0 84.0
P value <0.001 <0.001 <0.001
Abbreviations: H28 Seegene Anyplex™ II HPV28, Pos Positive, Neg Negative, N number
aAny high-risk HPV: HPV 16 and/or HPV18 and/or HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
bHPV16/18: HPV16 and or HPV18
cThe proportion of positive agreement between paired cobas and H28 samples was calculated using 2a/(f1 + g1), where a is the number of samples that were
positive for HPV in both tests, f1 is the number of samples that were positive for cobas, and g1 is the number of samples that were positive for H28
Table 2 H28 HPV results and semi-quantification of ß-globin DNA load, stratified on delay between sampling and laboratory
processing of DNA extraction (2 to ≥4 weeks)
HPV results ß-globin DNA loada p value
Undetectable + ++ +++ Total
N (%) N (%) N (%) N (%) N (%)
2 weeks
Positive 1 (2.3) 1 (2.3) 32 (74.4) 9 (20.9) 43 (100.0) <0.001
High-riskb 0 1 (3.3) 23 (76.7) 6 (20.0) 30 (100.0)
Low-riskc 1 (4.6) 0 17 (77.3) 4 (18.2) 22 (100.0)
Negative 0 0 26 (65.0) 14 (35.0) 40 (100.0)
Invalid 3 (60.0) 2 (40.0) 0 0 5 (100.0)
3 weeks
Positive 2 (3.5) 4 (7.0) 38 (66.7) 13 (22.8) 57 (100.0) <0.001
High-riskb 1 (2.3) 4 (9.1) 30 (68.2) 9 (20.5) 44 (100.0)
Low-riskc 1 (3.9) 2 (7.7) 18 (69.2) 5 (19.2) 26 (100.0)
Negative 0 0 50 (72.5) 19 (27.5) 69 (100.0)
Invalid 5 (38.5) 8 (61.5) 0 0 13 (100.0)
≥4 weeks <0.001
Positive 4 (3.7) 6 (5.5) 79 (72.5) 20 (18.4) 109 (100.0)
High-riskb 2 (2.4) 5 (6.1) 57 (69.5) 18 (22.0) 82 (100.0)
Low-riskc 3 (4.6) 3 (4.6) 51 (78.5) 8 (12.3) 65 (100.0)
Negative 0 0 62 (72.9) 23 (27.1) 85 (100.0)
Invalid 20 (71.4) 8 (28.6) 0 0 28 (100.0)
TOTAL 35 (7.8) 29 (6.5) 287 (63.9) 98 (21.8) 449 (100.0)
Abbreviations: N number
aUndetectable, absence of signal; + (low), positive >40 PCR cycles, <102 copies/reaction; ++ (medium) positive within 31 to 39 PCR cycles, ≥102 and < 105 copies/
reaction; +++ (high) positive before 31 PCR cycles, ≥ 105 copies/reaction
bPositivity for a high-risk HPV type (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69, 73 and 82)
cPositivity for a low-risk type (6, 11, 40, 42, 43, 44, 54, 61 and 70)
NB For multiple infections positive results were pooled and a single result was generated
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Fig. 1 Kaplan-Meier failure estimate showing the proportion of H28 invalid HPV tests over the days. HPV test analysis was done in a minimum
time of 15 days following the sampling
Vassilakos et al. Infectious Agents and Cancer  (2016) 11:13 Page 5 of 8not yet available [20]. In view of these considerations,
this study was designed to assess the validity of self-HPV
using dry swabs.
Our results indicate that dry swabs provided sufficient
amounts of biological material and stable DNA forTable 3 H28 HPV positive results and semi-quantification of
HPV-DNA load, stratified on delay between sampling and




HPV-DNA loada p value
+ ++ +++ Total
N (%) N (%) N (%) N (%)
2 weeks
High-riskb 20 (44.4) 25 (55.7) 0 45 (100.0) 0.009
Low-riskc 9 (34.6) 12 (46.2) 5 (19.2) 26 (100.0) 0.009
3 weeks
High-riskb 22 (37.9) 30 (51.7) 6 (10.3) 58 (100.0) 0.919
Low-riskc 11 (34.4) 18 (56.3) 3 (9.4) 32 (100.0) 0.919
≥4 weeks
High-riskb 38 (30.4) 75 (60.0) 12 (9.6) 125 (100.0) 0.409
Low-riskc 20 (21.0) 58 (66.7) 9 (10.3) 87 (100.0) 0.491
TOTAL 120 (32.2) 218 (58.5) 35 (9.4) 373 (100.0)
Abbreviations: N number
a + (low), positive >40 PCR cycles, <102 copies/reaction; ++ (medium) positive
within 31 to 39 PCR cycles, ≥102 and < 105 copies/reaction; +++ (high) positive
before 31 PCR cycles, ≥ 105 copies/reaction
bPositivity for a high-risk HPV type (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56,
58, 59, 66, 68, 69, 73 and 82)
cPositivity for a low-risk type (6, 11, 40, 42, 43, 44, 54, 61 and 70)
NB: For multiple infections each single positive result was counted for high- and
low-risk typeshrHPV detection by two PCR-based tests (cobas and
H28). Agreement between the two real-time PCR assays
for the detection of any HPV among the 14 hrHPV types
was 89.9 % (kappa = 0.77), despite different technologies
and cut-off algorithms. A similarly-strong agreement
was observed after the hierarchical categorization of
hrHPV types into two groups, according to cancer risk
(HPV-16/18 and pool of others).
We investigated the quality of the samples by analys-
ing the relationship between HPV test results and the
DNA load. The human reference gene ß-globin, a
marker for cellularity, and the HPV-DNA for 19 hrHPV
and 9 lrHPV were semi-quantified. Our findings are in
line with other studies indicating that the quality of a
dry specimen is sufficient for HPV detection [12] but
the delay between sampling and HPV detection may inter-
fere in the successful amplification of the reference gene
for internal control, generating invalid results [21, 22].
The failure to detect DNA load over time is probably be-
cause of genomic DNA degradation in some samples [21].
Baay et al. [22] compared ß-globin concentrations and
purity in vaginal samples self-collected by college students
on-site to samples that were collected at home and mailed
to the study laboratory with a delay ranging from 1 to
23 days (mean 4 days). They observed that DNA yield de-
creased with longer transport time; however, this had only
a minimal effect on PCR amplification. Lin et al. [23],
using a referral population, evaluated the stability of sam-
ples collected with dry swabs and tested with the cobas
4800 HPV test. They found that sample stored at an ambi-


























Cobas (14 hr types) H28 (14 hr types)
Fig. 2 Age-specific HPV prevalence (%) according to cobas and H28 real-time PCR tests. Abbreviations: H28 = Seegene Anyplex II HPV28; hr =
high-risk; NB: For multiple infections, results were pooled and a single positive result was generated
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high-grade cervical intraepithelial lesion or cancer. Our
findings confirm that stability of DNA in the sample col-
lected with a dry swab is maintained, however, specimens
processed after 2 weeks were more likely to be invalid for
analysis. Concerning the strength of the HPV-DNA load,
no detectable impact of the transport time was found on
the signal strength (p = 0.206) and the strength of HPV-
DNA load was not related to the strength of the ß-globin
DNA load (p = 0.154). Interestingly, in 7 samples with
undetectable ß-globin, PCR analysis with H28 revealed
positive HPV-DNA. This finding may corroborate the
hypothesis that HPV-DNA present predominantly as epi-
somal copies in dry samples is less affected from degrad-
ation [21].
Our data show that menopausal status does not affect the
quality of samples. Nevertheless, it should be noted that be-
sides DNA degradation because of the transportation time,
undetectable DNA may also be the result of an inadequate
sampling or the presence of PCR inhibitors [24].
This study provides for the first time information on
age-specific HPV prevalence in screened women in
Madagascar. Cobas and H28 were in agreement for the
overall prevalence rates found for 14 hrHPV types. The
pattern of HPV prevalence for the restricted age-range
of our study appeared similar to some surveyed African
countries, but different to others [25]. The observed
peak among women aged 45 years and older may be ex-
plained by newly acquired infections or by reactivation
of latent HPV infections [26].
The high HPV prevalence found among the screened
Malagasy women is consistent with published meta-
analyses for Eastern Africa. Systematic reviews reported
a HPV prevalence of 33.6 % [25] and 42.2 % [27] inwomen with normal cytology. The comparison of our
data on HPV type distribution with other African coun-
tries [27, 28], indicates that the epidemiology of HPV in-
fection is different in the study area. Differences in age
pattern of HPV prevalence and type distribution in
countries and regions may be related to different sexual
habits and migrations of people [29].
In this study we used simple cotton swab for sample
collection. Flocked swabs were found to have higher sen-
sitivity to detect HPV infection compared to Dacron
swabs [30], which was explained by its higher capacity of
adhesion leading to a better proportion of DNA.
However, in more recent studies [31, 32], no differ-
ence was found between the two swabs types for
DNA retrieval.
We do recognize that the approach for HPV testing
and subsequent follow-up applied in this study is unreal-
istic for a routine CC screening program in Madagascar.
Besides invalid samples, a long delay between screening
and reporting the results may lead to increased dropout
of HPV-positive women who need to be recalled for
management. A solution is the use of emergent rapid
PCR-based methods for detecting HPV-DNA, with
minimal requirements for laboratory equipment, en-
abling primary screening and treatment in a single
visit. Another limitation in our analysis is the lack of
histopathological results for all tested women, which
would be useful as gold-standard for both PCR
methods.
Because estimates of HPV prevalence and type-
specific distribution in Madagascar are necessary for
orienting CC prevention and monitoring the impact
of vaccination, our study needs to be completed with
estimates of a wider age range (15–60 years).
Table 4 Type-specific prevalence in mono and multi-infections according to the H28 real-time PCR test
HPV type
distribution
Mono-infections Multi-infections Total p value *
N (%) N (%) N (%)
High-risk types (HR) 0.277
16 3 (21.4) 11 (78.6) 14 (6.1)
18 6 (46.2) 7 (53.9) 13 (5.7)
26 1 (50.0) 1 (50.0) 2 (0.9)
31 6 (46.2) 7 (53.9) 13 (5.7)
33 7 (50.0) 7 (50.0) 14 (6.1)
35 5 (33.3) 10 (66.7) 15 (6.6)
39 1 (50.0) 1 (50.0) 2 (0.9)
45 3 (27.3) 8 (72.7) 11 (4.8)
51 4 (44.4) 5 (55.6) 9 (4.0)
52 4 (22.2) 14 (77.8) 18 (7.9)
53 5 (20.8) 19 (79.2) 24 (10.5)
56 5 (38.5) 8 (61.5) 13 (5.7)
58 4 (57.1) 3 (42.9) 7 (3.1)
59 5 (50.0) 5 (50.0) 10 (4.4)
66 2 (16.7) 10 (83.3) 12 (5.3)
68 8 (38.1) 13 (61.9) 21 (9.2)
69 0 2 (100.0) 2 (0.9)
73 2 (10.5) 17 (89.5) 19 (8.3)
82 1 (11.1) 8 (88.9) 9 (4.0)
All 72 (31.6) 156 (68.4) 228 (100.0)
Low-risk types (LR) 0.202
6 6 (66.7) 3 (33.3) 9 (6.2)
11 0 2 (100.0) 2 (1.4)
40 2 (13.3) 13 (86.7) 15 (10.3)
42 10 (40.0) 15 (60.0) 25 (17.2)
43 4 (30.8) 9 (69.2) 13 (9.0)
44 7 (35.0) 13 (65.0) 20 (13.8)
54 6 (21.4) 22 (78.6) 28 (19.3)
61 2 (25.0) 6 (75.0) 8 (5.5)
70 9 (36.0) 16 (64.0) 25 (17.2)
All 46 (31.7) 99 (68.3) 145 (100.0)
TOTAL (HR and LR) 118 (31.6) 255 (68.4) 373 (100)
*p value Mono-infections vs. Multi-infections
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In conclusion, our study provides evidence that self-
HPV with dry swabs stored at room temperature is a
valid alternative for screening with HPV testing in low
resource settings or remote areas, though HPV analysis
should be performed ideally within 2 weeks. Moreover,
our findings suggest that unsupervised self-sampling
with dry swabs in conjunction with a PCR-based method
is feasible in conducting population-based surveys onHPV prevalence, which are limited or missing in many
LMIC.Ethical approval
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